In order to decrease this delayed CINV, the investigators have developed a unique schedule
of antiemetics that takes advantage of palonosetron's long elimination half-life (40 hours).
In this study, patients will receive ondansetron 8mg and dexamethasone 10mg intravenously
30 minutes prior to myeloablative preparative chemotherapy until the last day of
chemotherapy. On the final day of chemotherapy, palonosetron 0. 25mg and dexamethasone 10mg
will be administered intravenously 30 minutes prior to the chemotherapy. If the
chemotherapy regimen is only 1 day of the chemotherapy then only palonosetron and
dexamethasone will be administered 30 minutes prior to chemotherapy. Dexamethasone 8mg once
daily will be given orally for 2 days following chemotherapy. The investigators hypothesize
that this antiemetic schedule will significantly reduce the delayed CINV compared to
historical controls

Clinical Details

Official title: A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy